Tadalafil Dosage Guide: 2.5/5/10/20 mg Research Protocols

Quick answer

Two dosing patterns appear in published tadalafil research, and they are not interchangeable. Daily 2.5 or 5 mg produces a steady-state plasma concentration in approximately 5 days and is the basis for the regulatory-approved BPH/LUTS indication and for continuous-coverage ED protocols. On-demand 10 or 20 mg produces a 36-hour activity window from a single dose, with 20 mg the highest approved on-demand strength. Food does not meaningfully alter tadalafil absorption, which distinguishes it from sildenafil and vardenafil and is the operational reason daily-dose protocols are practical. Most research protocols titrate from a starting dose based on baseline response and tolerability.

Table of contents

1. The two dosing patterns: daily-low-dose vs as-needed
2. 2.5 mg daily protocol
3. 5 mg daily protocol
4. 10 mg as-needed protocol
5. 20 mg as-needed protocol
6. Titration logic
7. Food, alcohol, and timing
8. Frequently asked questions
9. References

---

The two dosing patterns: daily-low-dose vs as-needed

Tadalafil has two regulatory-approved dosing patterns and a large published evidence base for each. The choice between them is operational, not pharmacological. The drug is the same molecule with the same target. Steady-state plasma kinetics differ.

Daily low-dose (2.5 or 5 mg). A single tablet taken at the same time each day. The 17.5-hour elimination half-life means plasma concentration accumulates: at steady state (reached in approximately 5 days, equal to 7 elimination half-lives by the standard pharmacokinetic rule of thumb), the trough concentration is approximately 1.6-fold higher than the trough after a single dose. The clinical effect is continuous PDE5 inhibition without peak-trough swings. According to PubMed, three randomized double-blind placebo-controlled multicenter trials demonstrated significant superiority of once-daily tadalafil at 2.5, 5, and 10 mg over placebo across validated measures of erectile function (Porst et al., 2009, PMID 19756466, DOI).

On-demand (10 or 20 mg). A single tablet taken approximately 30 minutes to 2 hours before activity. Plasma concentration peaks at approximately 2 hours and remains above the threshold for clinically meaningful PDE5 inhibition for approximately 36 hours after a 20 mg dose. The 36-hour window covers most plausible activity timing without re-dosing.

A randomized phase II trial in patients with post-radiotherapy ED randomized 52 men to either on-demand 20 mg or once-daily 5 mg for 12 weeks. Both regimens produced significant improvements in all International Index of Erectile Function (IIEF) domains. Treatment compliance was higher in the once-daily 5 mg arm (100 percent versus 86 percent on-demand), and there was a non-statistically-significant trend toward fewer adverse events in the daily arm (Ricardi et al., 2010, PMID 21711479, DOI).

The decision between the two patterns is made on use-case fit: daily for predictable continuous coverage, on-demand for flexibility on per-event dosing. Both have well-characterized safety profiles in long-term use.

2.5 mg daily protocol

The 2.5 mg dose is the lowest approved daily strength. It is used in three contexts in the published research base:

• Initial titration. Some protocols begin at 2.5 mg for the first week, then escalate to 5 mg if response is inadequate. The titration approach reduces first-week side-effect burden, particularly for headache and back pain, both of which often attenuate with continued dosing.
• Long-term continuous protocols. For research protocols requiring multi-month exposure, 2.5 mg daily delivers steady-state PDE5 inhibition with the lowest cumulative dose. This is relevant when the question being asked concerns long-term endothelial function, biomarker drift, or pulmonary hemodynamics rather than peak-effect pharmacodynamics.
• Step-down from 5 mg. When a researcher experiences ongoing tolerability issues at 5 mg daily but wants to maintain a daily-dose pattern, stepping down to 2.5 mg is a published option.

Steady-state at 2.5 mg daily is reached in approximately 5 days. The pharmacokinetic accumulation is modest at this dose and the side-effect burden is correspondingly the lowest of any approved tadalafil regimen.

5 mg daily protocol

The 5 mg once-daily dose is the most-studied tadalafil regimen in the published literature. It has multiple regulatory-approved indications including ED, BPH/LUTS, and combined ED+BPH. According to PubMed, dose-ranging and confirmatory studies that supported regulatory approval in the United States and Europe demonstrated that 12 weeks of once-daily tadalafil 5 mg produced statistically significant improvements in the total International Prostate Symptom Score (IPSS), the BPH Impact Index, IPSS subscores, IPSS quality-of-life scores, and the IIEF. Improvements occurred regardless of patient age, baseline LUTS severity, prior alpha-blocker exposure, or coexisting ED status (Carson et al., 2014, PMID 24341303, DOI).

The long-term safety pool for 5 mg daily is the most extensive of any tadalafil dose. According to PubMed, an integrated analysis of 12 phase II and phase III randomized double-blind placebo-controlled trials evaluated 5 mg once-daily tadalafil in men with LUTS/BPH, including a sub-population aged 75 years and older. No clinically relevant differences in long-term tolerability were observed between younger and older men, and there was no signal of increased cardiovascular adverse events at 5 mg daily compared with placebo (Oelke et al., 2017, PMID 27988986, DOI).

For research protocols with continuous-coverage requirements, 5 mg daily is the default starting point: most-studied, broadest safety pool, and the dose with the published BPH/LUTS evidence. Steady-state is reached in approximately 5 days; full washout after the last dose requires approximately 3 to 4 days.

10 mg as-needed protocol

The 10 mg on-demand dose is the lowest approved as-needed strength. It is the typical starting point for on-demand titration in published protocols. Onset is approximately 1 to 2 hours after oral administration. The activity window remains the 36-hour standard, the same as the 20 mg dose, because the determinant is the elimination half-life rather than the dose magnitude.

The 10 mg dose is preferred over 20 mg in two scenarios:

• Initial on-demand exposure, where tolerability is the open question. Side-effect rates (headache, back pain, dyspepsia) are dose-dependent, and starting at 10 mg surfaces tolerability issues at lower exposure.
• Adequate response at 10 mg, where titration to 20 mg adds dose-related adverse events without measurable efficacy gain.

Compared to 20 mg, the side-effect burden at 10 mg is approximately 30 to 50 percent lower across most reported AE categories, while efficacy in the modal patient population is roughly 60 to 80 percent of the 20 mg ceiling. The trade-off favors 10 mg as the initial exposure with titration up if needed.

20 mg as-needed protocol

The 20 mg on-demand dose is the highest approved tadalafil strength in regulatory monographs. It is reserved for patients who do not achieve adequate response at 10 mg and who tolerate the 10 mg dose without dose-limiting adverse events.

Operational details:

• Timing. Take 30 minutes to 2 hours before activity. Effects begin approximately 1 to 2 hours after dosing and remain present for approximately 36 hours.
• Frequency. No more than one 20 mg dose per 24-hour period in published protocols. The half-life means a second dose within 24 hours produces a higher AUC than the cumulative two-dose pattern would suggest, with disproportionate side-effect burden.
• Re-dosing. Within the 36-hour activity window, re-dosing is not recommended. The window is already covered by the initial dose.

The 20 mg dose carries the highest published rates of headache (10 to 15 percent), back pain (5 to 7 percent), and flushing (5 percent). Dyspepsia and nasal congestion rates are also elevated relative to 10 mg.

The 20 mg dose pairs well with a 24- to 48-hour rest interval before the next planned dose. This matches the half-life biology and prevents accumulation that would otherwise increase trough plasma concentration and the associated AE rate.

Titration logic

A practical titration approach across the published research base:

1. Choose pattern. Daily for continuous coverage, on-demand for per-event dosing. The decision is based on use-case fit, not on starting tadalafil-naive vs experienced.
2. Start at the standard initial dose. For daily, 5 mg (or 2.5 mg if tolerability is the leading concern). For on-demand, 10 mg.
3. Wait for steady state. For daily, 5 days minimum before assessing efficacy. For on-demand, 2 separate dosing exposures with adequate timing window.
4. Titrate up if response is inadequate. Daily 2.5 mg to 5 mg, or 5 mg to 20 mg daily (off-label, research only). On-demand 10 mg to 20 mg.
5. Titrate down if side effects are limiting. Daily 5 mg to 2.5 mg. On-demand 20 mg to 10 mg. If side effects persist at the lowest dose, the appropriate decision is discontinuation rather than further reduction.
6. Switch patterns if neither dose tier suits the use case. A researcher who started on-demand and finds the timing inflexible can switch to daily; a daily-protocol researcher who experiences cumulative side effects can switch to on-demand.

The overarching principle is the same as in any dose-titration framework: lowest effective dose for adequate response. Tadalafil’s flat dose-response curve at the upper end of the approved range means most response gains occur in the 5 mg to 10 mg range. Beyond 20 mg per dose, exposure increases without proportional efficacy improvement.

Food, alcohol, and timing

Food. Tadalafil’s absorption is not meaningfully affected by food, including high-fat meals. This is a notable difference from sildenafil and vardenafil, both of which show reduced absorption with high-fat meal co-administration. The food-independent absorption profile is the operational reason daily-dose protocols are practical. According to PubMed, this difference among PDE5 inhibitors is well-established in pharmacokinetic comparisons (Corbin and Francis, 2002, PMID 12166544).

Alcohol. Moderate alcohol consumption (up to approximately 3 standard drinks) does not meaningfully alter tadalafil pharmacokinetics. Heavy alcohol can produce additive vasodilation and orthostatic hypotension, a pattern shared across all PDE5 inhibitors. The interaction is hemodynamic rather than pharmacokinetic.

Timing. For daily-dose protocols, consistent same-time-each-day administration produces the most stable trough concentration. Morning dosing is the most common pattern in published trials. For on-demand protocols, the 1- to 2-hour onset and 36-hour window allow flexibility on exact pre-activity timing.

Frequently asked questions

What is the standard tadalafil dose?
Two patterns: 2.5 to 5 mg once daily for steady-state, or 10 to 20 mg as-needed before activity. The 20 mg dose is the highest approved on-demand strength.

Does food affect tadalafil absorption?
No clinically meaningful interaction. Unlike sildenafil and vardenafil, tadalafil absorption is not reduced by a high-fat meal. This is one reason daily-dose patterns are practical.

Can tadalafil be split or stacked?
Splitting a 20 mg tablet to approximate 10 mg is common in research. Stacking (taking a second dose within the half-life window) is not recommended. The long half-life means concentrations are still elevated and a second dose risks elevated AUC and increased side-effect burden.

How is tadalafil titrated?
Most published protocols start at 10 mg as-needed, titrate to 20 mg if response is inadequate, or to 5 mg if side effects (headache, back pain) are limiting. Daily-dose protocols typically start at 2.5 mg and titrate to 5 mg over 1 to 2 weeks.

What about alcohol?
Moderate alcohol (≤3 standard drinks) does not meaningfully alter tadalafil pharmacokinetics. Heavy alcohol can produce additive vasodilation and hypotension, similar to other PDE5 inhibitors.

References

References sourced via PubMed.

---

Research use only. Not medical advice. Tadalafil is Schedule F in Canada.

Related reading

• Tadalafil pillar guide
• Tadalafil protocol: ED, BPH, off-label endurance
• Tadalafil side effects
• Tadalafil vs sildenafil